key: cord-0729265-8sq7ftmd authors: Malhotra, S.; Mani, K.; Lodha, R.; Bakhshi, S.; Mathur, V. P.; Gupta, P.; Kedia, S.; Sankar, J.; Kumar, P.; Kumar, A.; Ahuja, V.; Sinha, S.; Guleria, R.; Consortium, COVID Reinfection AIIMS title: Effectiveness of BBV152 vaccine against SARS-CoV-2 infections, hospitalizations, and deaths among healthcare workers in the setting of high delta variant transmission in New Delhi, India date: 2022-01-24 journal: nan DOI: 10.1101/2022.01.22.22269701 sha: 6f90666a8981424b6113037900293e29e85a5eda doc_id: 729265 cord_uid: 8sq7ftmd Background: Delta variant transmission resulted in a surge of SARS CoV-2 cases in New Delhi, India during the early half of the year 2021. Health Care Workers (HCWs) received vaccines on priority for the prevention of infection. The real-life effectiveness of the BBV152 vaccine against severe disease including hospitalization and death was not known. Objective: To estimate the effectiveness of BBV152 vaccine among HCWs against SARS CoV-2 infection, hospitalization, or death Design: Observational study Setting: a multi-specialty tertiary care public-funded hospital in New Delhi, India. Participants: 12,237 HCWs Interventions: BBV152 vaccine (Covaxin, Bharat Biotech Limited, Hyderabad, India); whole virion inactivated vaccine; two doses four weeks apart Measurements: vaccine effectiveness after receipt of two doses of BBV152 protecting against any SARS CoV-2 infection, symptomatic infections or hospitalizations or deaths, and hospitalizations or deaths. Results: The mean age of HCWs was 36(11) years, 66% were men and 16% had comorbidity. After adjusting for potential covariates viz age, sex, health worker type category, body mass index, and comorbidity, the vaccine effectiveness (95% Confidence Interval) in fully vaccinated HCWs and two weeks elapsed after the receipt of the second dose was 44% (37 to 51, p<0.001) against symptomatic infection, hospitalization or death due to SARS CoV-2, and 61% (37 to 76, p<0.001) against hospitalization or death, respectively. Conclusions: BBV152 vaccine with complete two doses offers a modest response to SARS CoV-2 infection in real-life situations against a backdrop of high delta variant community transmission. Efforts in maximizing receipt of full vaccines should be invested for HCWs, who are at higher occupational risk for infection. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. ; https://doi.org/10.1101/2022.01. 22 .22269701 doi: medRxiv preprint 14 . Aman Dua Data curation, investigation, project administration, writing review and editing 15. Shafi Ahmad Data curation, investigation, project administration, writing review and editing 16. Vikas Gaur Data curation, investigation, project administration, writing review and editing 17. Divya Madan Data curation, investigation, project administration, writing review and editing 18. Anvita Data curation, investigation, project administration, writing review and editing 19. Shubi Virmani Data curation, investigation, project administration, writing review and editing 20. Ramadass Sathiyamoorthy Data curation, investigation, project administration, writing review and editing 21. Shilpi Chaudhary Data curation, investigation, project administration, writing review and editing 22. Swarnabha Sarkar Data curation, investigation, project administration, writing review and editing 23. Sakshi Shukla Data curation, investigation, project administration, writing review and editing 24. Ajay Sharma Data curation, investigation, project administration, writing review and editing 25. Arti Gupta Data curation, investigation, project administration, writing review and editing 26. Nidhi Yadav Data curation, investigation, project administration, writing review and editing 27. Tabbu Sakya Data curation, investigation, project administration, writing review and editing 28. Surbhi Sachdeva Data curation, investigation, project administration, writing review and editing 29. Shilpa Sharma Data curation, investigation, project administration, writing review and editing 30. Sachin Singh Data curation, investigation, project administration, writing review and editing 31. Abhimanyu Pandey Data curation, investigation, project administration, writing review and editing 32. Swetambri Sharma Data curation, investigation, project administration, writing review and editing 33. Amol Kumar Lokade Data curation, investigation, project administration, writing review and editing 34. Atif Mohammad Data curation, investigation, project administration, writing review and editing 35. Sabitri Pandit Data curation, investigation, project administration, writing review and editing 36. Ritu Pandey Data curation, investigation, project administration, writing review and editing 37. Mukesh Singh Data curation, investigation, project administration, writing review and editing . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 24, 2022. Interval) in fully vaccinated HCWs and ≥ 14 days elapsed after the receipt of second dose was 44% (37 to 51, p<0.001) against symptomatic infection, hospitalization or death due to SARS CoV-2, and 61% (37 to 76, p<0.001) against hospitalization or death, respectively. Conclusions: BBV152 vaccine with complete two doses offer a modest response to SARS CoV-2 infection in real life situations against a backdrop of high delta variant community transmission. Efforts in maximizing receipt of full vaccines should be invested for HCWs, who are at higher occupational risk for infection. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The COVID-19 pandemic is continuing with multiple waves, which have been attributed to newer SARS-CoV-2 variants and waning immunity. Delta variant is the globally predominant circulating strain (1) . India contributes to enormous high global case load with second largest cases reported (>34 million) so far in the world (2) . The capital of India witnessed a recent surge of cases and experienced a second wave during months of March to May 2021, with a daily test positivity rate as high as 36% (3) and the surge in cases has been attributed to the delta variant (4). India is also running one of the largest inoculation drives against COVID-19 with over 1 billion doses administered so far (5). Health Care Workers (HCWs) were the first priority group included for vaccination, starting from 16 January 2021. Two vaccines are being used-BBV152 (Covaxin, Bharat Biotech limited, Hyderabad) and ChAdOx1 (Covishield, Serum Institute of India, Pune). BBV152 is a whole virion inactivated vaccine with use of algel-IMDG (Imidazoquinoline molecule chemisorbed on alum) adjuvant to prime cell-mediated immune response (6) . The complete series is with 2 doses administered, 4 weeks apart. The phase 3 trial of BBV152 vaccine conducted within India, reported efficacy of 78% and 93% against symptomatic and severe symptomatic infection (7) . Recently, Covaxin has been included in the list for emergency use by World Health Organization (8) . The efficacy of ChAdOx1 has been established outside Indian setting (9) . Real world effectiveness of COVID-19 vaccines is one of the important research priorities (10) . Infection following COVID-19 vaccination is increasingly being reported after use of different vaccine types (11) (12) (13) . Estimates of ChAdOx1 vaccine effectiveness are available in different settings, including for delta variant, both in India and other countries (14) (15) (16) . There is no previous real time study reporting BBV152 vaccine effectiveness against hospitalization and death due to SARS-CoV-2 (17) . We aimed to report effectiveness of BBV152 vaccine against SARS CoV-2 infections, hospitalizations and deaths among health care workers, in a setting of predominant transmission due to delta variant. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 24, 2022. ; https://doi.org/10.1101/2022.01.22.22269701 doi: medRxiv preprint It was an observational study which collected data from different HCWs employed at the All-India Institute of Medical Sciences (AIIMS), New Delhi, India, a public-funded, teaching and multi-speciality tertiary care institute. The contact details of all HCWs (22, 723) were obtained from administrative division, that maintains service records of all the HCWs within the Institute. The study period in this report was considered April 10 to June 24, 2021. All employees (regular/contractual) and students at AIIMS were eligible to participate. Following categories of health care workers were invited to participate in the study: a) physicians (faculty, senior and junior residents and medical officers), b) nursing personnel, c) administrative and clerical staff, d) sanitation staff, e) security staff, f) social service supervisors, g) dietetics and related staff, h) laboratory personnel, i) technicians, j) research staff, k) scientists, l) health workers/ supervisors, m) paraclinical support staff, and n) students (medical, nursing, other undergraduates). Throughout the pandemic, AIIMS has been running a special employees' health clinic for testing and management of COVID-19. Only BBV152 vaccine was offered at AIIMS and rolled out on 16 January 2021 onwards. HCWs who received Covishield were excluded from the current report. All employees and students were contacted through e-mail, social media platforms like WhatsApp, and on telephone during May 12 to June 24, 2021. The data was collected either through a self-administered quality assurance measures in-built and web-based form (Google LLC, Mountain View, CA) or through telephone interview by trained personnel. The questionnaire included demographics (age/ gender/ type of HCW), co-morbidities, self- telephonically to enquire about deaths during the study period, using the verbal autopsy . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 1 3 method (18) . All HCWs, who reported infection and 20% of not infected, were contacted again to validate the reported findings through vaccination cards and test reports. 2. Severity of disease was graded as asymptomatic/ symptomatic; with details of symptomatic persons along with its severity (based on the World Health Organization (WHO) ordinal scale for clinical improvement), including hospitalization and death (19) . Participant with any of the following symptoms was considered symptomatic-fever, rhinorrhoea, sore throat, cough, chest pain, wheezing, difficulty in breathing, shortness of breath, anosmia, dysgeusia, fatigue, myalgia, headache, abdominal pain, nausea, and diarrhoea. 4 . Comorbidity considered were diabetes, hypertension, heart disease, chronic lung disease, chronic kidney disease, cancer, hypothyroidism and others. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. The probability of infection was estimated with respect to vaccination status using Kaplan-Meier curve and log rank test was used to compare the probability of infection among the groups. Next, we used the Poisson regression model between vaccination status and outcome controlling for demographic and clinical characteristics that could confound the association between vaccination and outcomes including age, sex, health care worker type, BMI and comorbidity status. From the estimated adjusted incidence rate ratio, we calculated the vaccine effectiveness (VE) by subtracting the incidence rate ratio from one (VE=1-incidence rate ratio). The p-value less than 0.05 was considered statistically significant. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. ; 1 5 This is shown in Figure 1 The distribution of HCWs with respect to baseline demographic and clinical characteristics as per vaccination status is shown in Table 1 and there were significant differences observed. Among the study participants, 2484 (20%) reported to have any SARS CoV-2 infection. The incidence of SARS CoV-2 infection among unvaccinated (A) and fully vaccinated (F) HCWs . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. The total person days contributed by unvaccinated and fully vaccinated HCWs were 167973 and 139020, respectively. The incidence density for any SARS CoV-2 infection events among unvaccinated and fully vaccinated HCWs was 62.9 (95% CI 59. 2 Figure 2 . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. as 89% (21) . In a cohort of HCWs based in England, the VE of BNT162b2 was 85%, 7 days after 2 doses (22) . The Indian COVID-19 VE estimates have been reported earlier for the Covishield vaccine. In a study from a south Indian multi-speciality hospital, the vaccine protection was reported as 65%, 77%, 92%, and 94% for prevention of infection, hospitalization, need for oxygen therapy and intensive care admission, respectively, though the estimates were unadjusted for any co-variates (14) . The reported estimates vary based on setting, type of vaccine and SARS-CoV-2 variant predominance during data collection period and methods used in estimating effectiveness. VE for m-RNA vaccines and ChAdOx1 nCoV-19 vaccine has been found to be reduced for protection against infection by delta variant (16) . A study from the United States (HEROES-RECOVER Cohorts) reported VE during the delta predominant period as 66% (95% CI: 26, 84) compared to 91% (81, 96) in months preceding delta predominance (23) . Convalescent sera of recipients of BBV152 in Indian setting were able to neutralize variants in broader B.1.617 lineage (24) . There was a clear contrasting difference between protection offered by single dose, which was low and inconsistent across the entire severity spectrum, compared to two dose schedules. This is corroborated by antibody measurement studies in HCWs that reported only 40% seropositive response after one dose as compared to 80% response after receipt of two doses of BBV152 (25) . We found higher vaccine effectiveness response in HCWs who had completed their vaccination after 10 April 2021, indicative of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. ; 1 8 varying effectiveness levels with shorter follow up intervals. On the contrary, the vaccine protection was not found in the partially vaccinated HCWs as on 10 April, indicating other unmeasured variables eliciting the response of the single dose of the vaccine, during the study period. Lower effect of partial dose was also reported with inactivated vaccine CoronaVac, compared to m-RNA vaccines (26) . For m-RNA vaccines, such low response for one dose was observed in case of delta variant, corroborated with laboratory neutralization studies (27) . From our institute, a genomic analysis study of 63 vaccine breakthrough infections (that included a sample of health care workers), 53 received BBV152 vaccine, and among them, B.1.617.2 was the predominant lineage detected in 13 fully vaccinated and 11 partially vaccinated patients (28) . Similar data have been reported from other centres (29, 30) . Breakthrough infections against delta variant have been reported from all the settings around the world against a variety of vaccines, by now (12, 13) . Our study had few limitations. In this observational study, some of the confounding due to residual covariates could not be omitted, though we adjusted our VE estimates for the known confounders including age, sex, type of health care worker, body mass index, and comorbidity status. There could be additional covariates like risk averse behaviour adopted by HCWs, that were not measured and reported, but could possibly influence effectiveness estimates. Vaccination status and other data were based on self-reports; however, sufficient details were captured and data were validated to authenticate the exposure and outcome data. We did not perform genomic analysis of SARS CoV-2 infections following vaccination reported in our study, though evidence from other studies was correlated and the delta variant was predominant lineage in transmission during the study period. We did not collect information about source of exposure of infection in our study HCWs. Also, some of the asymptomatic infections might be missed out, owing to lesser chances of them being tested. We anticipate in our setting that HCWs due to continuous exposures would get themselves tested more due to ready availability of testing and screening facilities within our Institute, though the possibility of varying rates of testing among different categories of HCWs could not be ruled out. HCWs are at increased risk of SARS CoV-2 infection due to occupational exposure and our results apply to them. The estimates for VE might not be generalizable to older people and other general community members. All those who were infected with COVID-19 earlier, prior to the roll-out of the vaccination . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. ; 1 9 programme, were excluded in this evaluation. Further, serological and immunological studies will be needed for examining long term immunity offered by the vaccine. Ours is a single site study, thus evidence from more settings will be needed for vaccine effectiveness. The strength of the study lies in generating evidence about BBV152 vaccine in real life situation. We followed STROBE guidelines for reporting the study (31) . symptomatic infection including hospitalization and death, among a cohort of HCWs in real world scenario. Our estimates for VE represent the setting when delta variant was predominant. In the absence of protective response with the partial receipt of BBV152, efforts for maximizing coverage with full dose schedule is vital. It is imperative that HCWs continue with COVID appropriate behaviour with use of personal protective equipment and follow distancing norms in order to maximize public health gains. The study did not receive any funding support. All investigators and authors received salary support from All India Institute of Medical Sciences, New Delhi. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. ; https://doi.org/10.1101/2022.01.22.22269701 doi: medRxiv preprint 2 3 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. ; 2 4 Table 1 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. Vaccination status (10 April 2021): * unvaccinated throughout; also includes those who were unvaccinated as of 10 April 2021 and had the outcome (infection) before getting first dose of the vaccine (Category A); ** fully vaccinated as of 10 April 2021 (Category F-Fa-fully vaccinated as of 10 April 2021 and second dose was received within 14 days prior to 10 APRIL 2021 and Fb-fully vaccinated as of 10 April 2021 and second dose was received >=14 days prior to 10 April 2021). CI-Confidence Interval. Any SARS-CoV-2 includes death or hospitalization or symptomatic disease or asymptomatic infection. a Vaccine Effectiveness VE is estimated using the Poisson regression model, VE=1-incidence rate ratio, and b incidence rate ratios were adjusted for age, sex, health care worker category, body mass index and comorbidity . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. Participants are health care workers who consented and either received at least one dose of BBV152 vaccine between 16 January 2021 and 24 June 2021 or did not receive vaccination. Analysis was carried out on 12237 participants to assess vaccine effectiveness among health care workers . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. World Health Organization. COVID-19 weekly epidemiological update World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2021 Delhi COVID integrated command and control centre dashboard-state level. Trend of positivity rate. Accessed at www.covid.dashboard.jantasamvad.org on Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial WHO issues emergency use listing for eighth COVID-19 vaccine Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Real world effectiveness of COVID-19 vaccines COVID-19 vaccine breakthrough case investigation and reporting Infection with the SARS-CoV-2 Delta variant is associated with higher infectious virus loads compared to the alpha variant in both unvaccinated and vaccinated individuals. medRxiv Transmission event of SARS-CoV-2 delta variant reveals multiple vaccine breakthrough infections Protective effect of COVID-19 vaccine among health care workers during the second wave of the pandemic in India COVISHIELD (AZD1222) VaccINe effectiveness among healthcare and frontline Workers of Indian Armed Forces: Interim results of VIN-WIN cohort study Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study Call for proper documentation of COVID-19 deaths in poor resource setting: a necessity for management of future occurrences Novel Coronavirus COVID-19 Therapeutic Trial Synopsis Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study Vaccine Effectiveness among Healthcare Personnel Study Team. Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B.1.617.2 (Delta) variant predominance -eight Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield TM ®) and BBV-152 (Covaxin TM ®) among health care workers in India: The final results of cross-sectional coronavirus vaccineinduced antibody titre (COVAT) study Effectiveness of an inactivated SARS-CoV-2 vaccine Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization Variants of Concern responsible for SARS-CoV-2 vaccine breakthrough infections from India SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion Clinical characterization and genomic analysis of samples from COVID-19 breakthrough infections during the second wave among the various states of India Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration We thank Dr. Rajiv Bahl, Department of Maternal, Newborn, Child and Adolescent Health and Ageing, World Health Organization, Geneva, Switzerland, for providing us scientific advice for analysing the data.